Immunotherapy with NK cells: recent developments in gene modification open up new avenues

Chimeric antigen receptor (CAR)-T cell therapies have achieved remarkable success. However, application-related toxicities, such as cytokine release syndrome or neurotoxicity, moved natural killer (NK) cells into focus as novel players in immunotherapy. CAR-NK cells provide an advantageous dual kill...

Descripción completa

Detalles Bibliográficos
Autores principales: Reindl, Lisa Marie, Albinger, Nawid, Bexte, Tobias, Müller, Stephan, Hartmann, Jessica, Ullrich, Evelyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781759/
https://www.ncbi.nlm.nih.gov/pubmed/33457093
http://dx.doi.org/10.1080/2162402X.2020.1777651
Descripción
Sumario:Chimeric antigen receptor (CAR)-T cell therapies have achieved remarkable success. However, application-related toxicities, such as cytokine release syndrome or neurotoxicity, moved natural killer (NK) cells into focus as novel players in immunotherapy. CAR-NK cells provide an advantageous dual killing-capacity by CAR-dependent and -independent mechanisms and induce few side effects. While the majority of trials still use CAR-T cells, CAR-NK cell trials are on the rise with 19 ongoing studies worldwide. This review illuminates the current state of research and clinical application of CAR-NK cells, as well as future developmental potential.

Ejemplares similares